Investigational Drug Details
| Drug ID: | D114 |
| Drug Name: | Doxycycline |
| Synonyms: | 5-hydroxy-α-6-deoxytetracycline; 6-alpha-deoxy-5-oxytetracycline; 6alpha-deoxy-5-oxytetracycline; 6α-deoxy-5-oxytetracycline; Anhydrous doxycycline; Doxycycline; Doxycycline (anhydrous); Doxycycline anhydrous |
| Type: | Chemical drug |
| DrugBank ID: | DB00254 |
| DrugBank Description: | Doxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline . This drug is a second-generation tetracycline, exhibiting lesser toxicity than first-generation tetracyclines . Doxycycline may be used to treat a wide range of bacterial infections, depending on the results of antibiotic susceptibility testing. |
| PubChem ID: | 54671203 |
| CasNo: | 564-25-0 |
| Repositioning for NAFLD: | No |
| SMILES: | O[C@@]12[C@H]([C@H](N(C)C)C(=C(C2=O)C(=O)N)O)[C@@H](O)[C@H]2C(=C1O)C(=O)c1c([C@@H]2C)cccc1O |
| Structure: |
|
| InChiKey: | JBIWCJUYHHGXTC-AKNGSSGZSA-N |
| Molecular Weight: | 444.44 |
| DrugBank Targets: | 16S ribosomal RNA binder |
| DrugBank MoA: | In bacterial replication, an interaction that is important for translation initiation of proteins occurs at the 3′ end of the 16S rRNA, found on the ribosome on the 30S subunit , , . The 30S subunit is the smaller subunit of the ribosome of prokaryotes, including bacteria. Tetracyclines such as doxycycline are thought to inhibit translation by binding to the 16S rRNA portion of the ribosome , preventing binding of tRNA to the RNA-30S bacterial ribosomal subunit, which is necessary for the delivery of amino acids for protein synthesis. As a result of the above actions, the initiation of protein synthesis by polyribosome formation is blocked. This stops the replication of bacteria and produces a bacteriostatic effect . |
| DrugBank Pharmacology: | The tetracyclines, including doxycycline, are mainly bacteriostatic and are thought to exert antimicrobial effects by the inhibition of protein synthesis. Bacteriostatic antibiotics suppress the growth of bacteria, or keep them in the stationary phase of growth . The tetracyclines, including doxycycline, have a similar antimicrobial spectrum of activity against a variety of gram-positive and gram-negative microorganisms, treating numerous infectious diseases. Cross-resistance of these microorganisms to tetracyclines is a common occurrence . Doxycycline shows favorable intra-cellular penetration, with bacteriostatic activity on a wide range of bacteria . Doxycycline has antiparasitic effects , , . In addition to the above effects, this drug has demonstrated anti-inflammatory actions, which may help to manage inflammatory conditions such as rosacea . |
| DrugBank Indication: | Doxycycline is indicated for the treatment of various infections by gram-positive and gram-negative bacteria, aerobes and anaerobes, as well other types of bacteria. A complete list of organisms is available in the FDA label and in the "indications" section of this drug entry . The following are some of the major infections that may be treated with doxycycline : Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (ornithosis) caused by Chlamydia psittaci Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis Nongonococcal urethritis caused by Ureaplasma urealyticum Relapsing fever due to Borrelia recurrentis **A note regarding anti-microbial resistance** It is important to note that doxycycline is not the drug of choice in the treatment of any type of staphylococcal infection. Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracyclines. Therefore, tetracyclines such as doxycycline should not be used to treat streptococcal infections unless the microorganism has been demonstrated to be susceptible . |
| Targets: | -- |
| Therapeutic Category: | -- |
| Clinical Trial Progress: | Clinical trial on-going (EUCTR2006-001774-24-GB) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0982 | EUCTR2006-001774-24-GB | Not applicable | Authorised | No Results Available | 18/09/2006 | 19 March 2012 | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00162 | 35203687 | Biomedicines | A Novel 2-Hit Zebrafish Model to Study Early Pathogenesis of Non-Alcoholic Fatty Liver Disease. | Details |
| A00175 | 35198900 | iScience | NAFLD indirectly impairs antigen-specific CD8+ T cell immunity against liver cancer in mice. | Details |
| A00873 | 34943942 | Cells | MXD3 Promotes Obesity and the Androgen Receptor Signaling Pathway in Gender-Disparity Hepatocarcinogenesis. | Details |
| A04134 | 33746082 | J Hepatol | The mitochondrial dicarboxylate carrier prevents hepatic lipotoxicity by inhibiting white adipocyte lipolysis. | Details |
| A04315 | 33668153 | Cancers (Basel) | MicroRNA-21 Plays Multiple Oncometabolic Roles in the Process of NAFLD-Related Hepatocellular Carcinoma via PI3K/AKT, TGF-β, and STAT3 Signaling. | Details |
| A05810 | 33110211 | Exp Mol Med | The impact of endotrophin on the progression of chronic liver disease. | Details |
| A10942 | 31112805 | J Glob Antimicrob Resist | Refractory Helicobacter pylori gastritis: The hidden predictors of resistance. | Details |
| A14905 | 29180630 | Sci Rep | ATF4 overexpression induces early onset of hyperlipidaemia and hepatic steatosis and enhances adipogenesis in zebrafish. | Details |
| A16782 | 28179883 | Front Pharmacol | New microRNA Biomarkers for Drug-Induced Steatosis and Their Potential to Predict the Contribution of Drugs to Non-alcoholic Fatty Liver Disease. | Details |
| A19123 | 26745268 | PLoS One | A Combination of Mitochondrial Oxidative Stress and Excess Fat/Calorie Intake Accelerates Steatohepatitis by Enhancing Hepatic CC Chemokine Production in Mice. | Details |
| A21013 | 25576488 | Mol Pharmacol | Repression of the nuclear receptor small heterodimer partner by steatotic drugs and in advanced nonalcoholic fatty liver disease. | Details |
| A25916 | 21331443 | Int J Mol Med | Association between lipid accumulation and the cannabinoid system in Huh7 cells expressing HCV genes. | Details |
| A52007 | 32408016 | Mol Metab | Suppressing adipocyte inflammation promotes insulin resistance in mice. | Details |